34 children's drugs are encouraged to apply for research and development! A billion varieties

[industry trends of pharmaceutical network] the National Health Commission recently issued the notice on printing and distributing the third batch of drugs encouraging research and development and application for children, and 34 varieties including clopidogrel, tacrolimus and voriconazole were encouraged to research and develop   According to the notice, in order to further implement the requirements of 6 departments such as the former national health and Family Planning Commission (gwyzf [2014] No 29) on safeguarding children's drug use, promote the R & D, creation and application review of appropriate varieties, dosage forms and specifications for children, and meet the needs of pediatric clinical drug use, the National Health Commission, the Ministry of industry and information technology, and the State Food and drug administration continue to closely focus on the spectrum of children's diseases in China And the R & D and production capacity of relevant enterprises, formulated the list of the third batch of drugs to encourage R & D and application for children From the list of the third batch of encouraged varieties for children's drug use, it can be found that there are many large varieties with sales of more than 1 billion in the domestic hospital market, such as clopidogrel, tacrolimus, voriconazole, etc In recent years, the safety of children's drug use has attracted much attention of the society Because children's drug use is relatively special, compared with adults' drug use, the R & D and utilization rate are relatively low, and there are few enterprises that can invest in R & D In order to encourage more pharmaceutical companies to research and develop children's medicine, China has taken a series of measures and given various support   For example, in terms of encouraging R & D application, on June 1, 2016, the list of the first batch of drugs for children to encourage R & D application was released, which listed 32 varieties such as Benzhexol, and encouraged manufacturers to apply for R & D; on May 31, 2017, the second batch of recommended list of drugs for children to encourage R & D application was released, and a total of 40 clinically urgently needed drugs for children were listed in the recommended list Step by step to solve the shortage of drugs for children in China Now the third batch of children's drug list is released It can be seen that almost every year a batch of children's drugs are released With more enterprises investing in the research and development of children's drugs, the shortage of children's drugs will be further improved, which is also conducive to better demand for children's drugs In fact, in 2019, the relevant encouragement and support policies for children's drug use have been constantly introduced Among them, the work plan for the adjustment of the national medical insurance drug catalogue in 2019 explicitly states that "priority should be given to the treatment of national essential drugs, cancer and rare diseases and other major diseases, chronic diseases, children's drugs, first aid and rescue drugs, etc." In addition, in the newly released list of Medicare drug catalog adjustment in August, there are also many new varieties of children's drugs Recently, the newly revised Drug Administration Law was voted through In terms of children's drugs, the state is specifically required to take effective measures to encourage the development and innovation of children's drugs, support the development of new varieties, dosage forms and specifications of children's drugs that meet the physiological characteristics of children, and give priority to the review and approval of children's drugs It is reported that in the next step, the drug regulatory department should study the specific relevant supporting rules and policies in the process of implementing the drug management law, issue the corresponding technical guidelines, and encourage and promote the development and innovation of children's drug use It can be seen that with the release of these favorable policies, the situation of the lack of dosage form specifications of special drugs for children in China will be gradually improved to better meet the needs of pediatric clinical medication The industry believes that at present, the market scale of children's medicine only accounts for 5% of the pharmaceutical industry, while the number of children accounts for about 16.6% of the national population Driven by the two child policy, the demand for children's medicine will continue to expand, and the market scale of children's medicine is expected to grow in the future, which will exceed 100 billion yuan For the pharmaceutical manufacturers listed in the list of incentives, they will get good development opportunities, and the market competition will be more intense in the future.